Phase 1
Completed N=18
Study of SHP620 (Maribavir) in Healthy Adults
Cytomegalovirus (CMV)
Source: ClinicalTrials.gov NCT02775240 ↗
Enrolled (actual)
18
Serious AEs
0.0%
Results posted
Jan 2019
Primary outcomePrimary: Maximum Observed Plasma Concentration (Cmax) of Digoxin — 1.94; 2.35 Nanogram per milliliter (ng/mL)
Summary
The purpose of this study is to determine how an investigational treatment (maribavir) is handled by the body when administered with two already approved drugs (digoxin and dextromethorphan). The study will also look at the safety and tolerability when maribavir is coadministered with digoxin and dextromethorphan versus digoxin and dextromethorphan alone.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Maximum Observed Plasma Concentration (Cmax) of Digoxin |
1.94; 2.35 | — |
| PRIMARY Maximum Observed Plasma Concentration (Cmax) of Dextromethorphan |
1.14; 1.14 | — |
| PRIMARY Maximum Observed Plasma Concentration (Cmax) of Dextrorphan |
433; 401 | — |
| PRIMARY Maximum Observed Plasma Concentration (Cmax) of Maribavir |
17.6 | — |
| PRIMARY Time to Reach Maximum Plasma Concentration (Tmax) of Digoxin |
1.00; 1.00 | — |
| PRIMARY Time to Reach Maximum Plasma Concentration (Tmax) of Dextromethorphan |
3.00; 3.00 | — |
| PRIMARY Time to Reach Maximum Plasma Concentration (Tmax) of Dextrorphan |
2.00; 2.00 | — |
| PRIMARY Time to Reach Maximum Plasma Concentration (Tmax) of Maribavir |
2.00 | — |
| PRIMARY Area Under the Plasma Concentration Versus Time Curve Extrapolated to Infinity (AUC0-infinity) of Digoxin |
31.6; 37.3 | — |
| PRIMARY Area Under the Plasma Concentration Versus Time Curve Extrapolated to Infinity (AUC0-infinity) of Dextromethorphan |
290.74; 179.19; 28.10; NA; NA; 25.14 | — |
| PRIMARY Area Under the Plasma Concentration Versus Time Curve Extrapolated to Infinity (AUC0-infinity) of Dextrorphan |
2270; 2150 | — |
| PRIMARY Area Under the Plasma Concentration Versus Time Curve From the Time of Dosing to the Last Measurable Concentration (AUClast) of Digoxin |
23.0; 26.7 | — |
| PRIMARY Area Under the Plasma Concentration Versus Time Curve From the Time of Dosing to the Last Measurable Concentration (AUClast) of Dextromethorphan |
7.06; 6.77 | — |
| PRIMARY Area Under the Plasma Concentration Versus Time Curve From the Time of Dosing to the Last Measurable Concentration (AUClast) of Dextrorphan |
2200; 2110 | — |
| PRIMARY Parent/Metabolite Ratio of Area Under the Plasma Concentration Versus Time Curve From the Time of Dosing to the Last Measurable Concentration (AUClast) for Dextromethorphan Over AUClast for Dextrorphan (AUClast Parent/Metabolite Ratio) |
0.003; 0.003 | — |
| PRIMARY Parent/Metabolite Ratio of Area Under the Plasma Concentration Versus Time Curve Extrapolated to Infinity (AUC0-infinity) for Dextromethorphan Over AUC0-infinity for Dextrorphan (AUC0-infinity Parent/Metabolite Ratio) |
0.177; 0.127; 0.009; NA; NA; 0.014 | — |
| PRIMARY Area Under the Plasma Concentration Versus Time Curve From Time Zero to the End of the Dosing Interval at Steady-State (AUCtau) of Maribavir |
91.5 | — |
| PRIMARY First-order Rate Constant (Lambda z) Associated With the Terminal (Log-linear) Portion of the Curve of Digoxin |
0.02; 0.02 | — |
| PRIMARY First-order Rate Constant (Lambda z) Associated With the Terminal (Log-linear) Portion of the Curve of Dextromethorphan |
0.04; 0.04; 0.08; NA; NA; 0.11 | — |
| PRIMARY First-order Rate Constant (Lambda z) Associated With the Terminal (Log-linear) Portion of the Curve of Dextrorphan |
0.16; 0.17 | — |
| PRIMARY Terminal Half-life (t1/2) of Digoxin |
41.5; 41.8 | — |
| PRIMARY Terminal Half-life (t1/2) of Dextromethorphan |
15.86; 16.17; 9.09; NA; NA; 6.43 | — |
| PRIMARY Terminal Half-life (t1/2) of Dextrorphan |
4.42; 4.16 | — |
| PRIMARY Terminal Half-life (t1/2) of Maribavir |
4.04 | — |
| PRIMARY Apparent Oral Clearance (CL/F) of Digoxin |
15.8; 13.4 | — |
| PRIMARY Apparent Oral Clearance (CL/F) of Dextromethorphan |
103.19; 167.42; 1067.64; NA; NA; 1193.51 | — |
| PRIMARY Apparent Oral Clearance (CL/F) of Maribavir |
2.19 | — |
| PRIMARY Concentration at the End of Dosing Interval (Ctau) of Maribavir |
2.13 | — |
| PRIMARY Volume of Distribution Divided by the Fraction of Dose Absorbed (Vz/F) of Digoxin |
946; 809 | — |
| PRIMARY Volume of Distribution Divided by the Fraction of Dose Absorbed (Vz/F) of Dextromethorphan |
2360.54; 3904.44; 14008.68; NA; NA; 11078.42 | — |
| PRIMARY Pre-dose Concentration (C0) of Maribavir |
2.64 | — |
| SECONDARY Number of Participants With Study-related Adverse Events (AEs), Serious Adverse Events (SAEs) and Treatment-emergent Adverse Events (TEAEs) |
4; 12; 0; 0; 4; 12 | — |
| SECONDARY Number of Participants With Clinically Significant Changes Reported as TEAE in Physical Examination, Vital Signs, 12-lead ECGs, Hematology, Blood Chemistry and Urinalysis |
0; 0; 0; 0; 0; 0 | — |
Eligibility Criteria
Inclusion Criteria
- An understanding, ability, and willingness to fully comply with study procedures and restrictions.
- Ability to provide written, personally signed, and dated informed consent to participate in the study, before completing any study-related procedures.
- Age 18-50 years, inclusive at the time of consent.
- Subjects must be willing to consent to and provide blood samples for pharmacogenomics analysis.
- Willingness to comply with any applicable contraceptive requirements of the protocol and is:
- Male, or
- Female of non-childbearing potential
- Non-pregnant, non-lactating female
- Females must be at least 90 days postpartum or nulliparous.
- Must be considered "healthy." Healthy status is defined by absence of evidence of any active or chronic disease following a detailed medical and surgical history, a complete physical examination including vital signs, 12-lead ECG, hematology, blood chemistry (includes T3, T4, and TSH at screening only), and urinalysis.
- Body mass index (BMI) between 18.5 and 30.0 kg/m2 inclusive.
- Hemoglobin is equal to or greater than 12.0g/dL.
- Ability to swallow a dose of investigational product (which may be multiple tablets at one time or consecutively 1 tablet at a time)
Exclusion Criteria
- Subject has a clinically significant history or a disorder detected during the medical interview/physical examination such as any cardiovascular, broncho-pulmonary, gastrointestinal (eg, inflammatory bowel disease, chronic diarrhea), hepatic, biliary (including gallbladder removal), renal, hematological, endocrine, autoimmune, neurological, or psychiatric disease (including depression) or any other medical condition that is capable of altering the absorption, metabolism, or elimination of drugs; or of constituting a risk factor when taking the investigational product in the judgment of the investigator.
- Known or suspected intolerance or hypersensitivity to the investigational product(s), closely related compounds, or any of the stated ingredients.
- Significant illness, as judged by the investigator, within 2 weeks of the first dose of investigational product.
- Known history of alcohol or other substance abuse within the last year.
- Donation of blood or blood products (eg, plasma or platelets) within 60 days prior to receiving the first dose of investigational product.
- Within 30 days prior to the first dose of investigational product:
- Have used an investigational product (if elimination half-life is 139 mmHg or 89 mmHg or 450 msec at screening.
- A positive screen for alcohol or drugs of abuse at screening or Day -1, Period 1.
- Male subjects who consume more than 21 units of alcohol per week or 3 units per day; female subjects who consume more than 14 units of alcohol per week or 2 units per day (1 alcohol unit=1 beer or 1 wine [5 oz/150 mL] or 1 liquor [1.5 oz/40 mL] or 0.75 oz alcohol).
- A positive human immunodeficiency virus, hepatitis B surface antibody, or hepatitis C virus antibody screen.
- Use of tobacco in any form (eg, smoking or chewing) or other nicotine-containing products in any form (eg, gum, patch). Ex-users must report that they have stopped using tobacco for at least 30 days prior to receiving the first dose of investigational product.
- Routine consumption of more than 2 units of caffeine per day or subjects who experience caffeine withdrawal headaches. (One caffeine unit is contained in the following items: one 6 oz [180 mL] cup of coffee, two 12 oz [360 mL] cans of cola, one 12 oz cup of tea, or three 1 oz [85 g] chocolate bars. Decaffeinated coffee, tea, or cola are not considered to contain caffeine.)
- Prior screen failure, randomization, participation, or enrollment in this study or prior enrollment in a clinical study investigating maribavir.
- Current use (defined as use within 14 days prior to the first dose of investigational product) of any medication (including over-the-counter, herbal, or homeopathic preparations [eg, St. John's wort, g
Data sourced from ClinicalTrials.gov (NCT02775240). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.